Efficacy of high dose of arbekacin once daily administration for methicillin-resistant Staphylococcus aureus infection

Efficacy of high dose of arbekacin once daily administration for methicillin-resistant Staphylococcus aureus infection - Efficacy of high dose ABK for MRSA infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001770

Enrollment

Registered

2009-03-12

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methicillin-resistant Staphylococcus aureus infection

Interventions

Dose: Primary administartion dose is caluculated by ABK TDM software ver. 2.1. ABK is injected once daily by 60 minutes. recommended serum ABK concentratios are 20 micro g/ml at peak and 2 micro g/ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patinets with suspected or defined pneumonia or sepsis due to MRSA, who satisfied the all conditions below; Patients who are 1) hospitalized 2) above 20 years old 3) male or female 4) able to understand and sign the agreement of participation to this clinical trial. (subistitutional agreement of relatives to participate to trail is allowed)

Exclusion criteria

Exclusion criteria: Patients with 1) allergy to aminoglycoside drugs 2) hearing disturbance due to aminoglycoside 3) severe renal or live dysfunction 4) hemodialysis 5) pregnant or breast feeding 6) needs drugs which is prohibited to use in this protocol 7) BW: below 40mg 8) neutrophil count is below 500 /mm3 9) others; attending physician decided to inappropriate

Design outcomes

Primary

Measure	Time frame
Efficay and safety at the end of administartion	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026